Effects of Pulmonary Resection on Right Ventricular Function
Launched by ÇAĞRI ÖZDEMIR · Jun 20, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how lung surgery affects the heart’s right side, specifically how well the right ventricle (one of the heart’s chambers) works after the operation. Since lung surgery can sometimes cause breathing and heart problems afterward, this study uses ultrasound tests of the heart (called echocardiography) before and after surgery to see if there are changes in heart function. The researchers are particularly looking at a measurement that combines blood pressure in the lungs and how well the right ventricle moves, to better understand how the heart handles the changes after lung surgery.
Adults between 18 and 80 years old who are scheduled for lung surgery and are generally in fair health may be eligible to join this study. However, people with irregular heartbeats, certain kidney problems, previous lung surgeries, recent heart attacks, or some lung function issues will not qualify. If you join, you can expect to have heart ultrasound scans before and after your surgery to monitor your heart’s function. This study aims to help doctors better predict and manage heart and lung complications after lung surgery, potentially improving recovery and long-term health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18 to 80 years
- • ASA classification I-III
- • Patients scheduled to undergo lung resection in thoracic surgery
- Exclusion Criteria:
- • Patients with arrhythmia
- • Patients using antiarrhythmic drugs
- • Patients with renal failure requiring hemodialysis
- • Patients with a history of previous lung surgery
- • Patients with valvular heart disease
- • Patients with a history of angina pectoris or myocardial infarction within the past month
- • Patients with FEV1/FVC ratio below 60%
About çağrı özdemir
Çağrı Özdemir is a clinical trial sponsor dedicated to advancing medical research through the support and management of innovative clinical studies. Committed to upholding the highest standards of scientific integrity and patient safety, Çağrı Özdemir plays a pivotal role in facilitating the development of new treatments and therapies aimed at improving health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, Yenimahalle, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported